[go: up one dir, main page]

PE20090281A1 - Composicion antigenica liofilizada - Google Patents

Composicion antigenica liofilizada

Info

Publication number
PE20090281A1
PE20090281A1 PE2008000879A PE2008000879A PE20090281A1 PE 20090281 A1 PE20090281 A1 PE 20090281A1 PE 2008000879 A PE2008000879 A PE 2008000879A PE 2008000879 A PE2008000879 A PE 2008000879A PE 20090281 A1 PE20090281 A1 PE 20090281A1
Authority
PE
Peru
Prior art keywords
tlr9
purine
antigenic composition
pyrimidine
lyophilized composition
Prior art date
Application number
PE2008000879A
Other languages
English (en)
Inventor
Francoise Mathilde Maurice Hogge
Dominique Ingrid Lemoine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/055037 external-priority patent/WO2007137986A2/en
Priority claimed from GB0723044A external-priority patent/GB0723044D0/en
Priority claimed from GB0723900A external-priority patent/GB0723900D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20090281A1 publication Critical patent/PE20090281A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION LIOFILIZADA QUE COMPRENDE UNO O MAS ANTIGENOS Y UN AGONISTA DEL RECEPTOR TIPO TOLL 9 (TLR9), DONDE EL ANTIGENO ES MAGE-3, CPC-P501S, WT-1, F4 Y gp120 Y EL ANTAGONISTA DE TLR9 ES UN OLIGONUCLEOTIDO INMUNOESTIMULADOR QUE COMPRENDE UNA SECUENCIA PURINA, PURINA, C, G, PIRIMIDINA, PIRIMIDINA. DICHA COMPOSICION LIOFILIZADA COMPRENDE UN VEHICULO SELECCIONADO DE SALES MINERALES, EMULSIONES, POLIMEROS, LIPOSOMAS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION
PE2008000879A 2007-05-24 2008-05-22 Composicion antigenica liofilizada PE20090281A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2007/055037 WO2007137986A2 (en) 2006-05-26 2007-05-24 Vaccination against cancer
GB0723044A GB0723044D0 (en) 2007-11-23 2007-11-23 Lyophillised antigen composition
GB0723900A GB0723900D0 (en) 2007-12-06 2007-12-06 Lyophillised antigen composition

Publications (1)

Publication Number Publication Date
PE20090281A1 true PE20090281A1 (es) 2009-03-28

Family

ID=39714209

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000879A PE20090281A1 (es) 2007-05-24 2008-05-22 Composicion antigenica liofilizada

Country Status (23)

Country Link
US (2) US20090035360A1 (es)
EP (3) EP2148697B1 (es)
JP (1) JP5331105B2 (es)
KR (2) KR20110091817A (es)
CN (1) CN101678091A (es)
AR (1) AR066676A1 (es)
AU (1) AU2008252911B2 (es)
BR (1) BRPI0811228A2 (es)
CA (1) CA2687632C (es)
CL (1) CL2008001491A1 (es)
CY (1) CY1113446T1 (es)
DK (1) DK2148697T3 (es)
EA (3) EA201300102A1 (es)
ES (1) ES2395333T3 (es)
HR (1) HRP20121019T1 (es)
MX (1) MX2009012381A (es)
PE (1) PE20090281A1 (es)
PL (1) PL2148697T3 (es)
PT (1) PT2148697E (es)
SI (1) SI2148697T1 (es)
TW (1) TW200911304A (es)
UY (1) UY31101A1 (es)
WO (1) WO2008142133A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028415A1 (en) 2005-04-12 2010-02-04 Haynes Barton F Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
US8956627B2 (en) * 2007-04-13 2015-02-17 Duke University Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates
CA2757240A1 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
EP3023106B1 (en) 2010-12-14 2019-07-31 GlaxoSmithKline Biologicals S.A. Mycobacterium antigenic composition
WO2013014105A1 (en) * 2011-07-22 2013-01-31 Glaxosmithkline Biologicals S.A. Prame purification
EP2802347B1 (en) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2898099C (en) 2013-01-15 2025-09-16 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 Peptides and Their Methods of Use
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
WO2015147899A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
WO2018104313A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
CA3106291A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827A (en) 1848-10-03 Improved table-cutlery
US666A (en) 1838-04-02 Sfbing-bock for coagh and railroad-gab
WO1988005054A1 (en) 1987-01-07 1988-07-14 Imperial Cancer Research Technology Limited Probe
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
AU745555B2 (en) * 1997-09-25 2002-03-21 Sloan-Kettering Institute For Cancer Research Fucosyl GM1-KLH conjugate vaccine against small cell lung cancer
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AU4823599A (en) 1998-06-22 2000-01-10 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes
DE69929444T2 (de) * 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
NZ513062A (en) 1999-01-29 2003-10-31 Smithkline Beecham HER-2/neu fusion proteins
CN100430478C (zh) 1999-03-11 2008-11-05 史密丝克莱恩比彻姆生物有限公司 Casb618多核苷酸和多肽及其用途
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
KR100848973B1 (ko) 2000-02-23 2008-07-30 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
MXPA04002631A (es) 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
EP1575611A4 (en) * 2002-12-23 2007-10-03 Hope City MODIFIED P53-EXPRESSING VACCINIAANKARA IN CANCER IMMUNOTHERAPY
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
CA2570271A1 (en) * 2004-06-12 2005-12-29 Pharma Pacific Pty Ltd. Method of enhancing the immune response to a vaccine
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006092017A1 (en) 2005-03-02 2006-09-08 Solbec Pharmaceuticals Limited Glycoalkaloid and tlr agonist combinations and various uses thereof
CA2612516C (en) * 2005-06-17 2015-03-24 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma

Also Published As

Publication number Publication date
US20090035360A1 (en) 2009-02-05
EA200901434A1 (ru) 2010-06-30
UY31101A1 (es) 2009-01-05
ES2395333T3 (es) 2013-02-12
PL2148697T3 (pl) 2013-02-28
EA018201B1 (ru) 2013-06-28
MX2009012381A (es) 2009-12-01
WO2008142133A1 (en) 2008-11-27
EP2148697A1 (en) 2010-02-03
TW200911304A (en) 2009-03-16
KR20100017519A (ko) 2010-02-16
PT2148697E (pt) 2012-12-24
EP2148697B1 (en) 2012-10-03
CN101678091A (zh) 2010-03-24
AR066676A1 (es) 2009-09-02
AU2008252911B2 (en) 2013-09-05
CL2008001491A1 (es) 2008-11-28
CA2687632C (en) 2013-01-15
US8557247B2 (en) 2013-10-15
HRP20121019T1 (hr) 2013-01-31
DK2148697T3 (da) 2012-12-17
JP5331105B2 (ja) 2013-10-30
EA201300102A1 (ru) 2014-02-28
US20110059163A1 (en) 2011-03-10
BRPI0811228A2 (pt) 2014-10-21
AU2008252911A1 (en) 2008-11-27
KR101238795B1 (ko) 2013-03-07
CY1113446T1 (el) 2016-06-22
CA2687632A1 (en) 2008-11-27
KR20110091817A (ko) 2011-08-12
SI2148697T1 (sl) 2013-01-31
EA201300101A1 (ru) 2014-02-28
JP2010527964A (ja) 2010-08-19
EP2489367A1 (en) 2012-08-22
EP2476431A1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
PE20090281A1 (es) Composicion antigenica liofilizada
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
MX2021005022A (es) Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
CO6680688A2 (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3(her3)
AR099812A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
CL2018003556A1 (es) Anticuerpos anti-ige.
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
EA201070329A1 (ru) Векторы и конструкции для доставки гриппозного антигена
AR076106A1 (es) Anticuerpos anti-cd40 y usos de los mismos
CL2019002270A1 (es) Conjugados de anticuerpo y fármaco anti-egfr. (divisional solicitud 201803527)
CY1118797T1 (el) Ανταγωνιστες toll-ωδους υποδοχεα 3
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
MX2013001845A (es) Polipetidos que enlazan miostatina, composiciones y metodos.
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
BR112019014986A2 (pt) anticorpo que alveja bcma e uso do mesmo
AR074501A1 (es) Oligonucleotidos inmunoestimuladores
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
PE20161152A1 (es) Anticuerpos y metodos de uso
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
MX2011000767A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
AR080111A1 (es) Metodos y composiciones de inmunizacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal